on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Pursues Strategic U.S. Growth Following Investor Spotlight
Onco-Innovations Limited has announced a strategic update focusing on their U.S. market expansion. This comes after CEO Thomas O'Shaughnessy's appearance on Cboe Canada's Investor Spotlight. The company aims to enhance cancer treatment technologies through innovation and AI-driven research.
Recent achievements include acquiring Inka Health AI, partnering with Dalton Pharma Services, and collaborating with the University of Alberta. Onco is preparing for a Phase 1 clinical trial in 2026, transitioning from preclinical research to clinical evaluation.
The company plans to cross-list on a U.S. stock exchange to expand investor access and strengthen ties with the North American research community. This strategy aims to boost shareholder value and support long-term growth.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news